The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55

Neuroscience Letters

Volumn 500, Issue 1, 2011, Pages 72-76

  Schuelert, Niklas ^a   McDougall, Jason J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Arthritis; Cannabinoids; Electrophysiology; Joint afferents; Nociception

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABIDIOL DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; O 1602; O 1918; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFECT; DRUG RECEPTOR BINDING; KNEE FUNCTION; MALE; NERVE FIBER C; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION;

ACTION POTENTIALS; ACUTE DISEASE; AFFERENT PATHWAYS; ANIMALS; ARTHRITIS; CANNABIDIOL; CARRAGEENAN; HINDLIMB; JOINTS; KAOLIN; MALE; MOVEMENT; NERVE FIBERS, UNMYELINATED; NOCICEPTION; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED;

EID: 79960330437     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.06.004     Document Type: Article

References (29)

1. Baker C.L., McDougall J.J. The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br. J. Pharmacol. 2004, 142:1361-1367.
2. Breivogel C.S., Griffin G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 2001, 60:155-163.
3. Costa B., Giagnoni G., Franke C., Trovato A.E., Colleoni M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br. J. Pharmacol. 2004, 143:247-250.
4. De Petrocellis L, Harrison S., Bisogno T., Tognetto M., Brandi I., Smith G.D., Creminon C., Davis J.B., Geppetti P., Di Marzo V. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J. Neurochem. 2001, 77:1660-1663.
5. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988, 34:605-613.
6. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nat. Rev. Drug Discov. 2008, 7:438-455.
7. Gauldie S.D., McQueen D.S., Pertwee R., Chessell I.P. Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints. Br. J. Pharmacol. 2001, 132:617-621.
8. Hajos N., Freund T.F. Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem. Phys. Lipids 2002, 121:73-82.
9. Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., Pertwee R.G., Ross R.A., Mechoulam R., Fride E. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:14228-14233.
10. Helyes Z, Sandor K., Borbely E., Tekus V., Pinter E., Elekes K., Toth D.M., Szolcsanyi J., McDougall J.J. Involvement of transient receptor potential vanilloid 1 receptors in protease-activated receptor-2-induced joint inflammation and nociception. Eur. J. Pain 2010, 14:351-358.
11. Hunter D.J., McDougall J.J., Keefe F.J. The symptoms of osteoarthritis and the genesis of pain. Rheum. Dis. Clin. N. Am. 2008, 34:623-643.
12. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A., Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:14136-14141.
13. Johns D.G., Behm D.J., Walker D.J., Ao Z., Shapland E.M., Daniels D.A., Riddick M., Dowell S., Staton P.C., Green P., Shabon U., Bao W., Aiyar N., Yue T.L., Brown A.J., Morrison A.D., Douglas S.A. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 2007, 152:825-831.
14. Just S., Pawlak M., Heppelmann B. Responses of fine primary afferent nerve fibres innervating the rat knee joint to defined torque. J. Neurosci. Methods 2000, 103:157-162.
15. Lauckner J.E., Jensen J.B., Chen H.Y., Lu H.C., Hille B., Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:2699-2704.
16. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
17. McDougall J.J. Peripheral analgesia: hitting pain where it hurts. Biochim. Biophys. Acta: Mol. Basis Dis. 2011, 1812:459-467.
18. McDougall J.J., Andruski B., Schuelert N., Hallgrimsson B., Matyas J.R. Unravelling the relationship between age, nociception and joint destruction in naturally occurring osteoarthritis of Dunkin Hartley guinea pigs. Pain 2009, 141:222-232.
19. McDougall J.J., Hanesch U., Pawlak M., Schmidt R.F. Participation of NK1 receptors in nociceptin-induced modulation of rat knee joint mechanosensitivity. Exp. Brain Res. 2001, 137:249-253.
20. McDougall J.J., Schuelert N., Bowyer J. Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis. Osteoarthritis Cartilage 2010, 18:1355-1357.
21. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
22. Patwardhan A.M., Jeske N.A., Price T.J., Gamper N., Akopian A.N., Hargreaves K.M. The cannabinoid WIN 55, 212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:11393-11398.
23. Pertwee R.G. GPR55: a new member of the cannabinoid receptor clan?. Br. J. Pharmacol. 2007, 152:984-986.
24. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 1999, 6:635-664.
25. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., Elebring T., Nilsson K., Drmota T., Greasley P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007, 152:1092-1101.
26. Schuelert N., Johnson M.P., Oskins J.L., Jassal K., Chambers M.G., McDougall J.J. Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis. Pain 2011, 152:975-981.
27. Schuelert N., McDougall J.J. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. Arthritis Rheum. 2008, 58:145-153.
28. Schuelert N., Zhang C., Mogg A.J., Broad L.M., Hepburn D.L., Nisenbaum E.S., Johnson M.P., McDougall J.J. Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain. Osteoarthritis Cartilage 2010, 18:1536-1543.
29. Staton P.C., Hatcher J.P., Walker D.J., Morrison A.D., Shapland E.M., Hughes J.P., Chong E., Mander P.K., Green P.J., Billinton A., Fulleylove M., Lancaster H.C., Smith J.C., Bailey L.T., Wise A., Brown A.J., Richardson J.C., Chessell I.P. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008, 139:225-236.